13 New Members Join DF/HCC

April 13,  2017

Thirteen individuals have recently joined DF/HCC. Learn more about these scientists and their research interests.

  • Khanh T Do, MD,

    After completing my fellowship in Medical Oncology and Hematology at the National Cancer Institute, National Institutes of Health in 2013, I pursued further drug development training in the Advanced Developmental Therapeutics Training Program (ADTTP) of the Division of Cancer Treatment and Diagnosis, National Cancer Institute. My training in this program exposed me to the various aspects of protocol development, the principles of biomarker development and incorporation of biomarkers that demonstrate proof-of-mechanism and target engagement in clinical trials. As part of my current appointment in the Early Drug Development Center (EDDC), Dana-Farber Cancer Institute, I am currently a co-investigator on several studies, and am the Principal Investigator for an Investigator-initiated study of prexasertib, CHK1 inhibitor, in combination with olaparib, PARP inhibitor. [Learn More...]

  • Jonathan Glickman, MD, PhD, MD PhD

    I am an anatomic pathologist with sub-specialty training in gastrointestinal pathology. My research interests include the evaluation and development of biomarkers of diagnostic or prognostic value in gastrointestinal cancers and their precursor conditions, including Barrett's esophagus and inflammatory bowel disease. In collaboration with laboratories at Brigham and Women's Hospital and Harvard School of Public Health, I also participate in studies of the regulation of intestinal T cells in colitis using murine models of colitis and inflammatory bowel disease models, and the role of intestinal microbial ecology in murine models of colitis and colorectal carcinogenesis. In clinical service I direct the gastrointestinal pathology division at Beth Israel Deaconess Medical Center, with extensive interface with the BIDMC Gastroenterology and GI Oncology groups. [Learn More...]

  • Yu Jing Jan Heng, PhD,

    I am a doctorally-trained scientist with a passion in translational medicine – applying novel technologies and analytical methods to better understand disease pathogenesis and the integration of various types of data (clinical, biobehavioral factors, epidemiological, genomics, proteomics etc.) to improve disease diagnostics and therapeutics in women’s health, such as breast cancer. [Learn More...]

  • Manuel Hidalgo, MD, PhD,
    Manuel Hidalgo, MD, PhD (Beth Israel Deaconess Medical Center)
    Developmental Therapeutics, Gastrointestinal Malignancies

    My research interests have centered in translational and clinical research in anticancer drug development with a particular emphasis in pancreatic cancer. We have led the early clinical development of more than 50 new anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer. Our most significant contribution has been the pioneering of patient derived xenograft models for drug screening, biomarker development and personalizes medicine in PDAC. Our immediate goal now is to incorporate immune treatment approaches both in preclinical models and in clinical studies in pancreas cancer. The National Cancer Institute has funded my research and I have been the recipient of a European Research Council advanced grant as well. [Learn More...]

  • Timothy Hla, PhD,
    Timothy Hla, PhD (Boston Children's Hospital)
    Angiogenesis, Invasion and Metastasis, Cancer Cell Biology

    Our laboratory has studied the role of lipid mediators in vascular system, inflammation and cancer. We cloned the human cyclooxyrgenase-2 (COX-2) cDNA and showed that this gene is correlated with chronic inflammatory conditions and various cancers. We also developed a mouse model in which COX-2 is over expressed and showed that the induction of COX-2 is a major progression factor in tumorigenesis. A second area of research that we contributed is the area of sphingolipid signaling. My laboratory cloned and characterized the first sphingosine 1-phosphate (S1P) receptor and characterized the biology of this signaling system in vascular development, angiogenesis, inflammation and vascular homeostasis. We are exploring the biology of this lipid mediator in vascular and immune systems and developing novel therapeutic strategies based on the S1P pathway. [Learn More...]

  • Philip Kranzusch, PhD,

    My research demonstrates that cGAS defines a broad family of RNA oligonucleotide synthase enzymes in the human genome, creating a new field for future exploration of small RNA signaling. My proposed research outlines a strategy to use cGAS-STING signaling as a paradigm to understand how a single immune pathway can balance multiple signaling outputs. The long-term goal of my lab is to uncover novel human synthases that employ small RNA signals to control pathogen defense and cellular development, and to utilize these pathways as new bioactive molecules for cancer immunotherapy. [Learn More...]

  • Anna M. Krichevsky, PhD, PhD

    The work in the laboratory focuses on small regulatory RNA molecules, microRNAs, their role in brain tumors, and potential as novel therapeutic targets and biomarkers. We are also interested in the RNA-mediated intracellular communication between brain tumors and normal cells of their microenvironment. Our overall goal is to develop basic RNA research toward a cure for glioblastoma (GBM) and other brain tumors. [Learn More...]

  • Alarice Lowe, MD,

    I am a practicing cytopathologist and surgical pathologist who joined the faculty at Brigham and Women's Hospital in 2011. My translational research program encompasses the application of circulating tumor cells (CTCs) and cytopathology to tumor biomarker evaluation, with the goal of guiding cancer therapies based on data from cells obtained by minimally invasive techniques. As the director of the Brigham and Women's Hospital CTC Lab, I work with local and regional investigators to establish the relevance of CTCs, utility of CTCs in evaluating therapeutic response, and development of new CTC technologies. [Learn More...]

  • Elizabeth Anne Mullen, MD,

    As an academic clinician, I have developed expertise in Pediatric Renal Tumors, have regional and national leadership roles, and a strong international reputation in clinical expertise. I am the Program Leader and Institutional Disease Expert for Renal Tumors at DFCI/BCH. I am a member of the COG Renal Tumors Steering Committee, and am Chair of the Renal Tumors Biology and Classification Study, as well as the Vice-Chair for the protocol for Treatment of Very Low Risk and Standard Risk Wilms Tumor. My interest in the improvement of outcomes in pediatric renal tumor patients has lead a study of urine proteomics to identify urinary markers of high risk renal disease. I currently chair the COG working group for the development of the next therapeutic study for patients with Favorable Histology Wilms Tumor, which will aim to incorporate additional biologic markers in risk stratification. [Learn More...]

  • Robert D. Odze, MD,

    I am the Director of GI Pathology Division at Brigham and Women's Hospital and Professor of Pathology at Harvard Medical School. My main research interests include the pathology, pathogenesis, natural history and molecular biology of cancer development in chronic inflammatory conditions of the GI tract, most notably Barrett's esophagus and inflammatory bowel disease. This research focuses on the mechanisms of progression from chronic inflammation through various grades of dysplasia to adenocarcinoma. Other research interests include laboratory and animal research on the mechanisms involved in inflammation, and in the development, of Barrett's esophagus in patients with gastroesophageal reflux disease. I have authored more than 300 peer reviewed research papers, reviews, editorials and book chapters and I am the senior editor of the largest most comprehensive textbook of GI pathology titled "Surgical Pathology of the GI Tract and the Biliary tract and Pancreas" [Learn More...]

  • Osama Rahma, MD,
    Osama Rahma, MD (Dana-Farber Cancer Institute)
    Cancer Immunology, Gastrointestinal Malignancies

    I am a Medical Oncologist who specializes in GI Oncology, with a research focus on Cancer Immunotherapy. After finishing my fellowship training at NCI, I joined UVA to lead a Clinical and Translational Research Program in Hepatobiliary Cancer. I recently joined the Center for Immuno-Oncology and GI Oncology as a Member of the Faculty at DFCI to conduct immunotherapy clinical trials in a variety of malignancies, in addition to providing clinical care to patients with GI cancers. I also have an appointment as an Associate Physician in Medical Oncology at Brigham and Women’s Hospital. [Learn More...]

  • Xin Yuan, MD, DSc,

    The major focus of the lab is on the molecular basis of cancer development and progression. One of the focus areas is the molecular and functional contribution of the SOX9 developmental factor in prostate and breast cancers. We have discovered that SOX9 is an important convergence node of multiple signal pathways that are critical for the development and oncogenesis. These signal pathways include androgen receptor, WNT and ERG signals. SOX9 critically mediating these oncogenic signals and enhances tumor formation, invasion, treatment resistance and angiogenesis. The SOX9 signal pathway represents novel therapeutic targets for intervention and biomarkers for disease progression. [Learn More...]

  • Kai Zou, PhD,

    My main research interest is to discern the cellular and molecular mechanisms of defective skeletal muscle metabolism in relation to metabolic diseases (e.g. insulin resistance, type 2 diabetes) as well as cancer (e.g., prostate cancer) and how interventions, such as exercise and diet interventions could counteract these defects. My research experience during my PhD and postdoc training has provided me strong background of cellular and molecular metabolism, mitochondria physiology as well as muscle stem cell biology. s a junior faculty, I would like to apply my research background into cancer research and to explore the cellular mechanisms of mitochondria dysfunction and dysregulated glucose metabolism in cancer development. [Learn More...]